title: Effects of oligofructose on appetite profile, glucagon-like peptide 1 and peptide YY3-36 concentrations and energy intake.
abstract: In rats, oligofructose has been shown to stimulate satiety hormone secretion, reduce energy intake and promote weight loss. The present study aimed to examine the effect of oligofructose supplementation on appetite profiles, satiety hormone concentrations and energy intake in human subjects. A total of thirty-one healthy subjects (ten men and twenty-one women) aged 28 (SEM 3) years with a BMI of 24·8 (SEM 0·3) kg/m(2) were included in a randomised double-blind, cross-over study. The subjects received 10 g oligofructose, 16 g oligofructose or 16 g placebo (maltodextrin) daily for 13 d, with a 2-week washout period between treatments. Appetite profile, active glucagon-like peptide 1 (GLP-1) and peptide YY3-36 (PYY) concentrations and energy intake were assessed on days 0 and 13 of the treatment period. Time × treatment interaction revealed a trend of reduction in energy intake over days 0-13 by oligofructose (P = 0·068). Energy intake was significantly reduced (11 %) over time on day 13 compared with day 0 with 16 g/d oligofructose (2801 (SEM 301) v. 3217 (SEM 320) kJ, P < 0·05). Moreover, energy intake was significantly lower with 16 g/d oligofructose compared with 10 g/d oligofructose on day 13 (2801 (SEM 301) v. 3177 (SEM 276) kJ, P < 0·05). Area under the curve (AUC) for GLP-1 on day 13 was significantly higher with 16 g/d oligofructose compared with 10 g/d oligofructose (45 (SEM 4) v. 41 (SEM 3) pmol/l × h, P < 0·05). In the morning until lunch, AUC(0-230 min) for PYY on day 13 was significantly higher with 16 g/d oligofructose compared with 10 g/d oligofructose and placebo (409 (SEM 35) v. 222 (SEM 19) and 211 (SEM 20) pg/ml × h, P < 0·01). In conclusion, 16 g/d and not 10 g/d oligofructose may be an effective dose to reduce energy intake, possibly supported by higher GLP-1 and PYY concentrations.
authors.affiliation: Department of Human Biology, Nutrition and Toxicology Research Institute Maastricht, Maastricht University, The Netherlands. s.verhoef@maastrichtuniversity.nl
authors.forename: Sanne P M
authors.initials: SP
authors.lastname: Verhoef
authors.forename: Diederick
authors.initials: D
authors.lastname: Meyer
authors.forename: Klaas R
authors.initials: KR
authors.lastname: Westerterp
mesh_terms: D000328:Adult; D001066:Appetite / Q000187:drug effects*; D019540:Area Under Curve; D018592:Cross-Over Studies; D004311:Double-Blind Method; D002149:Energy Intake; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000097:blood*; D006801:Humans; D008297:Male; D009844:Oligosaccharides / Q000009:adverse effects / Q000494:pharmacology*; D010446:Peptide Fragments; D019894:Peptide YY / Q000097:blood*; D010919:Placebos
chemical_list: D009844:Oligosaccharides; D010446:Peptide Fragments; D010919:Placebos; C120489:oligofructose; D019894:Peptide YY; C061785:peptide YY (3-36); D052216:Glucagon-Like Peptide 1